For these patients, personalized treatments should address critical open questions such as how to manage ACE inhibitors [115] that are used in clinical practice for treating hypertension and other cardiovascular diseases: Although ACE inhibitors do not interfere directly with ACE2 activity [17], discrepancies exist regarding their effects on ACE2 expression levels in different tissues [116–118] raising the question of whether these drugs would be harmful for COVID-19 patients. Here, ACE2 is linked to COVID-19.